Title: Differential expression of Lutheran/BCAM regulates biliary tissue remodeling in ductular reaction during liver regeneration

Yasushi Miura¹,², Satoshi Matsui¹,³, Naoko Miyata¹, Kenichi Harada⁴, Yamato Kikkawa⁵, Masaki Ohmuraya⁶, Kimi Araki⁷, Shinya Tsurusaki¹,⁸, Hitoshi Okochi¹, Nobuhiro Goda², Atsushi Miyajima³, Minoru Tanaka¹,⁸

¹Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; ²Department of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan; ³Laboratory of Cell Growth and Differentiation, Institute of Molecular and Cellular Biosciences, The University of Tokyo, Tokyo, Japan; ⁴Department of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan; ⁵Department of Clinical Biochemistry, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan; ⁶Department of Genetics, Hyogo College of Medicine, Hyogo, Japan; ⁷Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan; ⁸Laboratory of Stem Cell Regulation, Institute of Molecular and Cellular Biosciences, The University of Tokyo, Tokyo, Japan

Keywords: Oval cell; Ductular Reaction; Regeneration; Integrin β1; Laminin

Contact Information: Minoru Tanaka, Ph.D., Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan. Tel: +81-3-3202-7181 (ext. 2866); Fax: +81-3-3202-7192; E-mail: m-tanaka@ri.ncgm.go.jp
**Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCAM, basal cell adhesion molecule; BEC, biliary epithelial cell; CDE, choline-deficient and ethionine-supplemented; CK19, cytokeratin 19; CRISPR/Cas9, clustered regularly interspaced short palindromic repeats / CRISPR-associated proteins 9; DDC, 3,5-diethoxycarbonyl-1,4-dihydrocollidine; ECM, extracellular matrix; EGF, epidermal growth factor; EpCAM, epithelial cell adhesion molecule; FACS, fluorescence activated cell sorting; FcR, fragment crystallizable region receptor; HGF, hepatocyte growth factor; Itgb1, integrin β1 chain; Lama5, laminin alpha5; LPC, liver progenitor cell; Lu, Lutheran blood group glycoprotein; PECAM; platelet endothelial cell adhesion molecule; TWEAK, tumor necrosis factor-related weak inducer of apoptosis

**Financial support:** This work was supported, in part, by Grants-in-Aid for Scientific Research on Innovative Areas (26110007 to M.T. and 26110001 to M.O.) and Scientific Research A (26253023 to A.M.) from the Japan Society for the Promotion of Science, Japan, and by Research Program (JP17be0304201 to M.T.) from Japan Agency for Medical Research and Development (AMED).

**Potential conflict of interest:** Nothing to report.
Abstract

Under chronic or severe liver injury, liver progenitor cells (LPCs) of biliary origin are known to expand and contribute to the regeneration of hepatocytes and cholangiocytes. This regeneration process is called ductular reaction (DR), which is accompanied by dynamic remodeling of biliary tissue. Although the DR shows apparently distinct mode of biliary extension depending on the type of liver injury, the key regulatory mechanism remains poorly understood. Here, we show that Lutheran (Lu)/Basal cell adhesion molecule (BCAM) regulates the morphogenesis of DR depending on liver disease models. Lu⁺ and Lu⁻ biliary cells isolated from injured liver exhibit opposite phenotypes in cell motility and duct formation capacities in vitro. By overexpression of Lu, Lu⁻ biliary cells acquire the phenotype of Lu⁺ biliary cells. Lu-deficient mice showed severe defects in DR. Our findings reveal a critical role of Lu in the control of phenotypic heterogeneity of DR in distinct liver disease models.
The liver is known to possess outstanding capacity for regeneration upon injury. In acutely injured or surgically resected livers, regeneration is usually achieved by proliferation and hypertrophy of residual hepatocytes (Fausto and Campbell, 2003; Miyaoka et al., 2012). By contrast, under chronic or severe liver injury that impairs the proliferation of hepatocytes, liver progenitor cell (LPC) has been postulated to contribute to liver regeneration by differentiating into hepatocytes and biliary epithelial cells (BECs), also known as cholangiocytes (Thorgeirsson, 1996; Fausto, 2004; Miyajima et al., 2014). This response is known as ductular reaction (DR), in which LPC/biliary cell with BEC marker expression proliferates from the portal areas of injured livers, forming pseudo-ductular structures. DRs are frequently observed in human chronic liver diseases and rodent models including fatty liver disease and cholangiopathy (Shafritz and Dabeva, 2002; Roskams et al., 2003; Gouw et al., 2011; Wood et al., 2014). In zebrafish models, biliary cells have been reported to contribute to regenerating hepatocytes after substantial loss of hepatocytes (Choi et al., 2014). In mouse models, accumulating evidence by in vitro assay or transplantation experiments of biliary cells supports the presence of potential LPC with clonogenicity and bi-lineage differentiation capacity in the biliary compartment (Suzuki et al., 2008a; Okabe et al., 2009; Dorrel et al., 2011; Lu et al., 2015). In addition, a recent study using in vivo genetic lineage tracing experiment demonstrated that biliary cells can regenerate hepatocytes as facultative LPC under impaired hepatocyte regeneration in mice (Raven et al., 2017). Thus, DR is considered as a process of liver regeneration in chronically injured liver. In fact, genetically manipulated mice with defects in DR have been reported to show impaired recovery from chronic liver injury (Ishikawa et al., 2012; Takase et al., 2013; Shin et al., 2015).
To explore the nature of LPC in DR, several mouse injury models have been developed previously. In particular, two dietary models using 3,5-Diethoxycarbonyl-1,4-DihydroCollidine supplemented (DDC) diet and choline deficient and ethionine-supplemented (CDE) diet have been extensively utilized to characterize LPC in mice for many years (Preisegger et al., 1999; Akhurst et al., 2001). Although both models induce massive DR, the pathological features resulting from these two methods are quite distinct; CDE-induced injury is thought to be a mouse model of non-alcoholic fatty liver disease with extensive hepatic damage (Knight et al., 2005; Ahanori-Simon et al., 2011), while DDC-induced injury is considered as a model of chronic cholangiopathy with portal biliary damage and severe cholestasis (Fickert et al., 2007). Considering the different pathological features of these two models, DR is assumed to be regulated depending on the severity and type of liver injury. In fact, it has been reported that morphological and functional heterogeneity of ductal cells is evident in DRs originating from many different pathological conditions in human patients and rodent models (Sell, 1998; Alvaro et al., 2007; Priester et al., 2010; Kaneko et al., 2015). Similar to such previous observations, CDE- and DDC-induced DR exhibited quite distinct morphology; the former extends outwards away from the portal vein, showing primitive ductules with spindle-like shape, while the latter remains around the portal vein, forming obvious bile duct-like structures. However, very little is known about the molecular mechanisms accounting for the phenotypic difference of DR among liver disease models.

In the present study, we identified Lutheran blood group glycoprotein (Lu) as a crucial molecule to control the morphological heterogeneity of DR. Lu, also known as Basal Cell Adhesion Molecule (BCAM) or CD239 is a member of the immunoglobulin superfamily, which is composed of five Ig-like domains on the extracellular site, a
single transmembrane domain and a short C-terminal cytoplasmic tail (Parsons et al., 1995). Lu is known as a laminin receptor, which has been studied in context of sickle cell disease (Udani et al., 1998; El Nemer et al., 1999), and is capable of binding to laminin-511/521 via laminin alpha5 (Lama5) chain (Parsons et al., 2001). It has been reported that Lu/BCAM is widely expressed in cells and tissues including hematopoietic cells, placenta and kidney, and is developmentally regulated in human liver (Parsons et al., 1995). However, the expression profile of Lu in mouse LPCs remains to be investigated. Here, we show that Lu is a robust marker to discriminate between CDE-induced and DDC-induced DR; Lu is highly expressed in proliferating biliary cells in the CDE model, but downregulated in the DDC model. By using fluorescence activated cell sorting (FACS), we have isolated Lu-positive and Lu-negative biliary cells from injured liver. By comparison of both biliary cells in scratch assay and cyst formation assay, we revealed a role for Lu in regulating the morphological heterogeneity of DR. Further analysis using Lu-deficient mice demonstrated that the extension of biliary tree was significantly suppressed during DR in the CDE-induced liver injury. Collectively, our findings demonstrate that Lu functionally regulates the remodeling of biliary tissue during liver regeneration, and provide new insights into the heterogeneity of LPCs among liver disease models.
Results

Lutheran is differentially expressed in CDE- and DDC-induced DR

We have previously identified Epithelial cell adhesion molecule (EpCAM) as a marker for murine LPC/BEC (Okabe et al., 2009). To investigate the difference in DRs between the CDE and DDC models, immunohistochemical analysis of EpCAM was performed. Both protocols of feeding CDE and DDC diet for 3 weeks induced robust DR accompanied by biliary cell expansion. However, the appearance of propagating ducts exhibited strikingly distinct features between two models; CDE-induced biliary cells displayed primitive capillary-like morphology, invading into the parenchymal area extensively, while DDC-induced biliary cells exhibited remarkable duct-like structure, remaining around the periportal area (Figure 1A). Similarly, immunostaining of CK19, another LPC marker, showed a pattern similar to that of EpCAM (Figure 1-figure supplement 1). Because most known LPC markers are uniformly expressed in both types of DR, these molecules may not account for the heterogeneity of LPC. Therefore, we examined the expression profile of Lu in both injury models, because we have identified Lu as a marker for hepatoblasts, a fetal type LPC during liver development. Co-staining of liver sections using anti-EpCAM and anti-Lu antibodies revealed that Lu was detected in extending biliary cells of the CDE-fed liver, whereas we could not find such signals in biliary cells of DDC-fed liver except intense signal in EpCAM⁺ ducts (Figure 1B). As reported by the previous paper that Lu is stained in hepatic arteries and portal vein of adult human liver (Parsons et al., 1995), co-staining of Lu and platelet endothelial cell adhesion molecule (PECAM), an endothelial marker, in the DDC-fed liver revealed that the EpCAM⁺ duct with strong fluorescence is hepatic artery (Figure 1-figure supplement 2). Next, to compare the expression level of Lu in biliary cells, we performed flow cytometric (FCM) analysis using anti-EpCAM and
anti-Lu antibodies. In untreated normal liver, FCM and immunohistochemical analyses demonstrated that most EpCAM$^+$ biliary cells showed moderate expression of Lu (Figure 1C and Figure1-figure supplement 3). By contrast, approximately 35% of EpCAM$^+$ cells in CDE-fed liver showed high expression of Lu, whereas nearly half of EpCAM$^+$ cells in DDC-fed liver exhibited low or negative expression of Lu (Figure 1C). These opposing expression profiles of Lu in the CDE and DDC models led us to hypothesize that Lu might regulate the morphological heterogeneity of expanding biliary cells between these distinct injury models.

**Isolation of biliary cells with a distinct level of Lu from chronically injured liver**

To uncover the role of Lu in regulating biliary cell morphology, we isolated Lu$^{\text{high}}$ and Lu$^{\text{low}}$ biliary cell fractions from CDE-injured livers by FACS, and then cultured each population. Although Lu is highly expressed in endothelial cells, we confirmed that a contamination of such cells in EpCAM$^+$ gating is highly unlikely as shown in Figure 2-figure supplement 1. We refer to these cultured biliary cells as Lu$^+$ BC and Lu$^-$ BC in the following studies. Interestingly, similar to the morphological characteristics of DR in vivo, Lu$^+$ BC displayed spindle-like shape while Lu$^-$ BC showed epithelial-like morphology even after several passages (Figure 2A). Fluorescent staining using Phalloidin demonstrated that the actin fibers and pseudopods are formed in the atypical cell body of Lu$^+$ BC while F-actin accumulates in the periphery of round-shaped cell body of Lu$^-$ BC (Figure 2B). By contrast, when freshly isolated EpCAM$^+$ cholangiocytes from untreated normal liver were cultured on the dish, the attached cells exhibited a mixture of round and indefinite morphology (Figure 2-figure supplement 2). Furthermore, FCM analysis of cultured Lu$^+$ BC and Lu$^-$ BC revealed that the expression profile of Lu was maintained in each cell; Lu$^{\text{high}}$-derived biliary
cells continued to express Lu at a high level, while Lu<sup>-flow</sup>-derived biliary cells hardly expressed Lu (Figure 2D). By contrast, several stem cell markers such as CD24 and CD44 were expressed similarly between Lu<sup>+</sup> BC and Lu<sup>-</sup> BC, suggesting that these cells are closely related, but distinct homogeneous populations.

**Comparison of cell motility and cyst forming capacity between Lu<sup>+</sup> BC and Lu<sup>-</sup> BC**

Considering that biliary cell with high expression of Lu in the CDE model exhibits an invasive phenotype *in vivo*, Lu<sup>+</sup> BC is expected to have a higher capacity for cell motility than Lu<sup>-</sup> BC. To compare the capacity for cell motility between Lu<sup>+</sup> BC and Lu<sup>-</sup> BC, we performed an *in vitro* scratch assay, by which the moving distance was evaluated after creating a scratch on the dish. As expected, Lu<sup>+</sup> BC showed significantly higher motility capacity than Lu<sup>-</sup> BC (Figure 3A), suggesting that there is a causal link between Lu expression level and cell motility.

On the other hand, biliary cells with low or no expression of Lu in the DDC model exhibited an obvious luminal structure around the portal vein *in vivo*, suggesting that Lu<sup>-</sup> BC has higher capacity for duct formation than Lu<sup>+</sup> BC. As previously reported, LPCs are able to form cyst-like luminal structures with biliary epithelial polarity in a three-dimensional (3D) organoid culture (Tanimizu et al., 2007). We thereby compared the cyst-forming capacity between Lu<sup>-</sup> BC and Lu<sup>+</sup> BC in the 3D culture system (Figure 3B). After 6 days of culture, Lu<sup>-</sup> BC formed a large number of cystic structures, while Lu<sup>+</sup> BC formed only small cell aggregates, demonstrating that Lu<sup>-</sup> BC has higher duct-forming capacity than Lu<sup>+</sup> BC (Figure 3C). Thus, Lu<sup>+</sup> BC and Lu<sup>-</sup> BC showed distinct features of cell motility and cyst formation *in vitro*. These results suggest that Lu may play a crucial role in the cell kinetics of biliary cell.
Lu- BC acquires the characteristics of Lu+ BC by overexpression of Lu

To investigate whether Lu expression is responsible for the characteristics of biliary cells, cDNA encoding either mouse Lu (mLu) and green fluorescent protein (GFP) or only GFP as a control was transduced into Lu- BC by retroviral vector. The mLu-transduced Lu- BC (Lu- BC-mLu) showed morphological change into a spindle-like shape, while GFP-transduced control (Lu- BC-GFP) retained a round shape (Figure 4A). In the scratch assay, Lu- BC-mLu showed higher mobility than Lu- BC-GFP (Figure 4B). In contrast, the cyst formation assay demonstrated the reduced cyst-forming capacity of Lu- BC-mLu, resulting in the formation of numerous small aggregates (Figure 4C). These results strongly suggested that Lu- BC acquired the Lu+ BC-like phenotype after Lu expression, and that Lu might endow biliary cells with characteristics of spindle shape morphology and enhanced motility.

Constitutive association of Lama5 with DR in chronically injured livers

Although the differential expression profile of Lu is likely to be relevant to the phenotypic heterogeneity of DR, the molecular mechanism by Lu remains unclear. Because Lu is known to be a receptor for Lama5 and bind to Laminin-511 and -521, we next investigated the expression of Lama5 in CDE- and DDC-injured livers. Intriguingly, double staining of EpCAM and Lama5 revealed that most expanding biliary cells are fully surrounded by Lama5 in both liver injury models (Figure 5A). Considering the accumulation of Lama5 in the vicinity of biliary cells, it is plausible that Lama5 may be secreted from biliary cell itself rather than the environmental niche cell. Indeed, the expression of Lama5 mRNA was verified in both EpCAM+ biliary cells isolated from CDE- and DDC-injured livers (Figure 5B), implying the involvement of
Laminins in Lu-driven regulation. While Lu is capable of binding to Laminin-511/521 via Lama5, these laminins are also known as a ligand for Integrinα3β1/α6β1 (Kikkawa et al., 2007). It has been reported that Lu binds to Lama5 competitively with Integrinα3β1/α6β1 and promotes tumor cell migration by modulating Integrin-mediated cell attachment to Laminin-511 protein (Kikkawa et al., 2013). Taking these evidences into account, Lu may regulate the morphogenesis of DR via an Integrin-mediated manner. Given that Lu plays a role in the competitive inhibition against Laminin-511/521 and Integrinα3β1/α6β1 axis in biliary cell as shown in Figure 5-figure supplement 1, high expression of Lu would be reproduced by inhibition of integrinβ1 (Itgb1) signaling. To address this possibility, we first investigated the expression of Integrinα3 (Itga3), Integrinα6 (Itga6) and Itgb1 in Lu− BC and Lu+ BC. As shown in Figure 5-figure supplement 2, all integrin components were expressed in Lu− BC and Lu+ BC, indicating that Lu− BC and Lu+ BC are potentially competent to cell signaling via Integrinα3β1/α6β1-Laminin-511/521 axis. We next examined the effect of neutralizing antibody against Itgb1 on the motility and duct formation capacity of Lu− BC in vitro. Although the inhibition of Itgb1 signaling did not affect the expression of Lu− (Figure 5-figure supplement 3), it dramatically changed Lu− BC to Lu+ BC-like phenotype in both scratch assay and cyst formation assay (Figure 5C and D). Conversely, we investigated the effect of Itgb1 activation on Lu+ BC. Because TS2/16 antibody has been reported to activate Itgb1 signaling (Rozo M et al., 2016), we added it to the 3D culture of Lu+ BC. As a result, Lu+ BC acquired cyst formation capacity by the activation of Itgb1 (Figure 5-figure supplement 4). These data strongly suggested that Lu regulates the characteristic of DR by modulating the Itgb1 signaling.
**Bcam KO mice show a key role for Lu in DR in CDE-induced liver injury**

To verify the role of Lu/Bcam in DR in vivo, we generated Bcam knockout (KO) mice, in which the 11 bp deletion within a signal sequence-coding region of exon1 resulted in the frame shift of the Bcam gene (Figure 6A and Figure 6-figure supplement 1). The Bcam KO mice were healthy, showing no obvious developmental abnormality as reported previously (Rahuel et al., 2008). To compare the phenotype of DR between Wild-type (WT) and Bcam KO mice, mice were fed a CDE or DDC diet for 3 weeks and then their livers were analyzed by immunohistochemistry for EpCAM. When mice were fed the CDE diet, the proliferation of biliary cells occurred in both WT and Bcam KO mouse livers (Figure 6B). The loss of Lu protein in KO mouse was confirmed by immunostaining for Lu (Figure 6C). To our surprise, Lu-deficient biliary cells failed to spread outwards from the portal vein while WT biliary cells extended into the parenchymal area. The migrating distance of biliary cells from the portal vein was significantly shorter in Bcam KO mice than WT mice (Figure 6D).

By contrast, in the DDC model, the migrating distance of biliary cells from the portal vein showed no significant difference between WT and Bcam KO mice (Figure 6D and E). However, a slight hyperplasia of duct-like structures was observed in Bcam KO mice in both DDC and CDE models (Figure 6F). Moreover, freshly isolated EpCAM⁺ biliary cells from WT CDE-fed mouse livers showed spindle-like shape and pseudopods on the dish, while those from Bcam KO mice predominantly exhibited rounder morphology resembling Lu⁺ BC (Figure 6G). These results suggested that Lu plays a critical role in the definition of morphological heterogeneity of DR in vivo.

**CD239 is expressed in DR in human liver disease.**

To investigate the expression of Lu/BCAM (CD239) in human liver disease, we
performed immunostaining of CD239 for a few resected samples obtained from the surgery to remove liver cancer. Intriguingly, CD239 was stained in DR in patients of chronic liver disease including non-alcoholic steatohepatitis, hepatitis B virus and hepatitis C virus (Figure 7), suggesting that the expression profile of Lu is conserved in humans.
Discussion

DR is often observed in various situations of chronic liver injury or submassive liver cell loss. A number of anatomical and histological analyses of human and rodent liver tissues have supported the notion that DR represents the expansion of LPC for supplying transit-amplifying cells to replenish the damaged hepatic cells. However, the origin and the role of LPC in liver regeneration is still under intensive debate. Recent lineage tracing experiments in mice have revealed that the hepatocytic differentiation of LPCs derived from the biliary compartment is negligible in DDC-induced liver injury (Malato et al., 2011; Español-Suñer et al., 2012; Tarlow et al., 2014; Rodrigo-Torres et al., 2014). This is reasonable because DDC-injury is a model of chronic cholangiopathy, which requires replenishment of cholangiocytes or bile ducts to be recovered. In fact, it has been reported that mice with impaired DR causes severe jaundice in the DDC model (Takase et al., 2013). Consistently, we observed many bile ducts with an obvious luminal structure in the DR of DDC-fed liver. Therefore, the downregulation of Lu in LPC may represent a process of cholangiocyctic differentiation and reinforcement of duct formation for bile excretion in the DDC model.

In contrast to the DDC-model, it is still controversial whether LPC may contribute to hepatocyte regeneration in other chronic liver injury models. The contribution of LPC derived from biliary component to hepatocyte regeneration has been reported in the CDE model using two different lineage tracing approaches based on BEC marker genes, Osteopontin (Spp1) and Hnf1β (Español-Suñer et al., 2012; Rodrigo-Torres et al., 2014), although to a much lesser extent. The valid but low contribution of LPC of biliary origin to hepatocytic differentiation may be explained by robust proliferation of mature hepatocytes, because hepatocyte-mediated regeneration is not inhibited in
the CDE model. This notion is strongly supported by a more recent report from Forbes’s group suggesting that a combination of CDE-injury and inhibition of hepatocyte proliferation causes physiologically significant and higher contribution of biliary cells to hepatic regeneration (Raven et al., 2017). Therefore, Lu-mediated high motility of LPC in the CDE model may contribute to the rapid delivery of hepatic progenitor cells to the damaged parenchymal area far from the portal vein.

In the DR, environmental factors play crucial roles in the regulation of LPC proliferation and differentiation. Several immune cell-derived cytokines such as TNF-related WEAK inducer of apoptosis (TWEAK), interleukin-6 and interleukin-22 have been shown to be pro-mitotic for LPCs (Jakubowski et al., 2005; Yeoh et al., 2007; Feng et al., 2012). Cell signaling pathways including Wnt, Notch, HGF and EGF are reportedly responsible for fate decisions of LPCs (Boulter et al., 2012; Fiorotto et al., 2013; Kitade et al., 2013). Although the regulatory mechanism of Lu expression in LPCs is unclear, these signaling pathways may be worthy of investigating.

Extracellular matrix (ECM) is also known to serve a niche for LPC regulation in chronic liver injury as well as liver development. Of note, laminin is an important component of LPC niche affecting cell fate decision. It has been reported that the escape of LPCs from the laminin basement favors their hepatocytic differentiation (Español-Suñer et al., 2012; Paku et al., 2004), while laminin aids maintenance of LPC and biliary cell phenotype (Lorenzini et al., 2009; Boulter et al., 2013). Consistently, it has been reported that Lama5 KO mice show defects in bile duct formation during liver development and that Itgb1 signaling is required for cholangiocytic differentiation from hepatoblast, a fetal-type LPC (Tanimizu et al., 2012). It is therefore highly probable that Itgb1 signaling in the context of laminin/integrin axis is crucial for biliary regeneration and duct formation from LPC.
Our in vitro data also supported the idea that Itgb1 signaling modulated by Lu expression may govern DR, depending on liver injury type.

It remains undetermined whether high expression of Lu in biliary cells is an essential step for hepatocytic differentiation. Alternatively, the up-regulation of Lu may provide LPC with a cue to escape from ECM-rich periportal area, as evidenced by Bcam KO phenotype in the CDE model. We showed that the downregulation of Lu in ductular reactive cells facilitated the cystogenic phenotype. However, the loss of Lu would be also expected for the hepatocytic differentiation from LPC because mature hepatocytes do not express Lu. In line with the idea, intriguingly, the expression of Lu seemed to be downregulated in EpCAM⁺ cells at the tip of DR in the CDE model (Figure 1B). The discrepancy may be explained by the microenvironment surrounding LPCs; the periportal region is rich in ECM including laminin whereas the parenchymal region is poor in it. Taking such microenvironment into consideration, the loss of Lu in parenchymal area may be a sign of hepatocytic differentiation by the escape of LPC from laminin deposition. Further expression analysis of Lu and Laminin with a combination of lineage tracing experiment will uncover the mechanism underlying LPC-mediated liver regeneration depending on the microenvironment.

In addition to the signaling molecules and ECM, several non-parenchymal cells have been shown to be involved in the microenvironment for LPC. Intriguingly, Hul et al. reported that prolonged Kupffer cell (KC) depletion did not influence the proliferation of LPCs but reduced their invasive behavior in the CDE model (Hul et al., 2011). The LPCs of KC-depleted mice exhibit phenotype resembling cells of biliary lineage with rounder morphology. More interestingly, the LPCs remain closer to the portal area, in places delineating a pseudo-lumen. This phenotypic change of LPCs by KC depletion closely resembles that of Bcam KO mice in the CDE diet. On the
other hand, Boulter et al. reported that hepatic macrophage played a role in promoting LPC specification to hepatocytes by expressing Wnt3a in the CDE model (Boulter et al., 2012). These evidences suggest that hepatic macrophages may be a key regulator of Lu expression in a process of LPC specification. Further studies using a lineage tracing experiment in Bcam KO mice under various types of chronic liver injuries will provide a clue to better understanding the molecular mechanisms underlying the phenotypic heterogeneity, as well as fate determination of LPCs during liver regeneration.

In conclusion, the present study demonstrates that the expression profile of Lu in biliary cells dramatically changes during DR depending on the type of liver injury, which in turn dictates the morphological characteristics of biliary cells such as cell motility and duct formation (Figure 8). This molecular mechanism would be expected to be conserved in human liver diseases. Thus, Lu is a novel marker for classification of DR and an interesting functional molecule for investigating the nature of LPCs. Our findings will provide new insights into the significance of biliary cell heterogeneity in liver regeneration.
### Materials and methods

#### Key Resources Table

<table>
<thead>
<tr>
<th>Reagent type</th>
<th>Designation</th>
<th>Source or reference</th>
<th>Identifiers</th>
<th>Additional information</th>
</tr>
</thead>
<tbody>
<tr>
<td>antibody</td>
<td>anti-EpCAM (rat monoclonal)</td>
<td>PMID: 19429791</td>
<td></td>
<td>(1:100-500)</td>
</tr>
<tr>
<td>antibody</td>
<td>anti-EpCAM (rabbit polyclonal)</td>
<td>Abcam</td>
<td>Abcam:ab71916; RRID:AB_1603782</td>
<td>(1:400)</td>
</tr>
<tr>
<td>antibody</td>
<td>anti-Lutheran (rat monoclonal)</td>
<td>this paper</td>
<td></td>
<td>(1:500)</td>
</tr>
<tr>
<td>antibody</td>
<td>anti-Sca1 (rat monoclonal)</td>
<td>BioLegend</td>
<td>BioLegend:108107; RRID:AB_313344</td>
<td>(1:400)</td>
</tr>
<tr>
<td>antibody</td>
<td>anti-CD24 (rat monoclonal)</td>
<td>Miltenyi Biotec</td>
<td>MB:130-102-731; RRID:AB_2656573</td>
<td>(1:400)</td>
</tr>
<tr>
<td>antibody</td>
<td>anti-CD71 (rat monoclonal)</td>
<td>Miltenyi Biotec</td>
<td>MB:130-109-632; RRID:AB_2659126</td>
<td>(1:400)</td>
</tr>
<tr>
<td>antibody</td>
<td>anti-CD44 (rat monoclonal)</td>
<td>Miltenyi Biotec</td>
<td>MB:130-110-117; RRID:AB_2658152</td>
<td>(1:400)</td>
</tr>
<tr>
<td>antibody</td>
<td>anti-FcR (rat monoclonal)</td>
<td>BioLegend</td>
<td>BioLegend:101320; RRID:AB_1574975 and RRID:AB_312801</td>
<td>(1:100)</td>
</tr>
<tr>
<td>antibody</td>
<td>anti-CK19 (rabbit polyclonal)</td>
<td>PMID:12665558</td>
<td></td>
<td>(1:1000)</td>
</tr>
<tr>
<td>antibody</td>
<td>anti-Lama5 (rabbit polyclonal)</td>
<td>PMID:9151674</td>
<td></td>
<td>(1:200)</td>
</tr>
<tr>
<td>antibody</td>
<td>anti-Ki67 (rat monoclonal)</td>
<td>ThermoFisher</td>
<td>ThermoFisher:14-5698-80; RRID:AB_10853185</td>
<td>(1:200)</td>
</tr>
<tr>
<td>antibody</td>
<td>anti-PECAM (rat monoclonal)</td>
<td>BD Biosciences</td>
<td>BD:553373; RRID:AB_394819</td>
<td>(1:100)</td>
</tr>
<tr>
<td>antibody</td>
<td>anti-CD31 (rabbit polyclonal)</td>
<td>Novus</td>
<td>NB:NB100-2284; RRID:AB_10002513</td>
<td>(1:100)</td>
</tr>
<tr>
<td>antibody</td>
<td>anti-CD239 (rabbit monoclonal)</td>
<td>Abcam</td>
<td>Abcam:2994-1; RRID:AB_2065309</td>
<td>(1:100)</td>
</tr>
<tr>
<td>antibody</td>
<td>anti-CD29</td>
<td>BD Biosciences</td>
<td>BD:555002;</td>
<td>5 μg/mL for 3D</td>
</tr>
<tr>
<td>Antibody</td>
<td>Supplier</td>
<td>Catalog Number/RRID</td>
<td>Concentration for 3D culture</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-------------------</td>
<td>-----------------------------------------</td>
<td>------------------------------</td>
<td></td>
</tr>
<tr>
<td>Anti-CD29 (mouse monoclonal)</td>
<td>BioLegend</td>
<td>BioLegend:303010; RRID:AB_314326</td>
<td>50 μg/mL for 3D culture</td>
<td></td>
</tr>
<tr>
<td>Hamster IgM, λ1 isotype (hamster monoclonal)</td>
<td>BD Biosciences</td>
<td>BD:553957; RRID:AB_479639</td>
<td>5 μg/mL for 3D culture</td>
<td></td>
</tr>
<tr>
<td>Mouse IgG1, κ isotype (mouse monoclonal)</td>
<td>BioLegend</td>
<td>BioLegend:401404</td>
<td>50 μg/mL for 3D culture</td>
<td></td>
</tr>
</tbody>
</table>

**Animal Models**

C57BL/6J mice were purchased from Clea-Japan, Inc. (Tokyo, Japan). All animals were maintained in a standard Specific-Pathogen-Free (SPF) room at the institutional animal facility. All animal experiments were performed according to institutional guidelines and approved by the Animal Care and Use committee of the Institute of Molecular and Cellular Biosciences, The University of Tokyo (approval numbers 2501, 2501-1, 2609, 2706, and 3004), Kumamoto University (approval number A27-092), Hyogo College of Medicine (approval number 16-043, 16-046), and National Center for Global Health and Medicine Research Institute (approval numbers 15080, 16023, 17086 and 18069). To induce liver injury, a diet containing 0.1 % DDC (Clea-Japan Inc. Tokyo, Japan) or the choline-deficient, ethionine-supplemented diet (MP Biomedicals, CA, USA) was fed to 6-week-old mice for 3 weeks.

**Study Approval for human samples**

The study using human samples was approved by the Kanazawa University Ethics Committee.
Committee (approval number 305-4), and all of the analyzed samples are derived from patients who provided informed written consent for the use of their tissue samples in research.

**Antibodies**

The information about antibodies used for FACS and immunohistochemistry is described in Key Resource Table. The rat anti-EpCAM monoclonal antibody was generated as described previously (Okabe et al., 2009). The rabbit anti-CK19 polyclonal antibody was generated as described previously (Tanimizu et al., 2003). The rat anti-Lutheran monoclonal antibody used in this study was generated by immunization of a rat with mouse fetal hepatic cells as described previously (Suzuki et al., 2008b), and biotinylated for FACS using ECL Protein Biotinylation Module (GE Healthcare UK Ltd, UK). The specific reactivity against mouse Lu was validated by flow cytometric (FCM) analysis of Ba/F3 cells transfected with Bcam cDNA by a retroviral vector, pMxs/IRES-GFP (Kitamura et al., 2003) (Figure 1-supplement 4). The anti-Lutheran monoclonal antibody (D295-3) and anti-EpCAM monoclonal antibody (D269-3) are commercially available from MBL International Corporation, MA, USA.

**Liver Perfusion and Cell Sorting**

Cells were isolated from murine livers as described previously (Okabe et al., 2009). Briefly, liver cells were dissociated by perfusion of collagenase solution. Non-parenchymal cells (NPCs) were prepared by removal of hepatocytes with repeated centrifugation at 100g for 2 minutes. Then, NPCs were incubated with anti-FcR antibody for blocking non-specific binding, followed by with fluorescein
isothiocyanate (FITC)-conjugated anti-EpCAM monoclonal antibody for 30 minutes on ice. After incubation with anti-FITC microbeads (1:10-100 dilution, Miltenyi Biotec, Bergisch Gladbach, Germany), EpCAM<sup>+</sup> cells were enriched by autoMACS pro (Miltenyi Biotec). After MACS, cells were incubated with biotin-conjugated anti-Lutheran monoclonal antibody for 30 minutes on ice. After wash, cells were incubated with allophycocyanin (APC)-conjugated streptavidin (1:100-500 dilution, BD bioscience, NJ, USA) for 20 minutes on ice and analyzed or purified by fluorescence-activated cell sorting (FACS) using Moflo XDP (Beckman-Coulter, CA, USA) and BD FACSCanto II (BD bioscience). Dead cells were excluded by propidium iodide (Sigma-Aldrich, MO, USA) staining.

**Cell Culture**

Sorted EpCAM<sup>+</sup> cells from CDE-fed mouse liver were cultured with modified William’s-E medium as previously reported (Okabe et al., 2009). For in vitro assay, the cells expanded at 3 to 6 passages were used. For cytoskeleton staining, Alexa Fluor 488 Phalloidin (1:500 dilution, Thermo Fisher Scientific, MA, USA) was used.

**Scratch Assay**

The cells were seeded in a 24-well plate at a confluency of 90-95% the day before scratch assay. After 12 to 24 hours of culture, the medium was removed and fresh medium with 10 μg/mL Mitomycin C (Wako Pure Chemical Industries) was added to fully confluent cells to inhibit further proliferation. The treated cells were incubated continuously for 150 minutes at 37°C. After incubation, the cell layer was scratched crosswise with a micropipette tip. Each well was washed twice with PBS to prevent detached cells from re-adhering. After creating the scratch, the cells were
continuously cultured without cytokines. The moving distance was calculated by subtracting the half of gap length at Day 1 from that at Day 0. For experiments of antibody administration, Hamster anti-rat CD29 (555002, BD Pharmingen) or Hamster IgM (553957, BD Pharmingen) was added in the culture at a final concentration of 1 μg/mL.

**Immunohistochemistry**

The resected left lobe of liver was embedded into OCT compound (Sakura Finetek Japan), and frozen by liquid nitrogen. The frozen block was cut into 8μm slices by Microtome Cryostat HM 525 (Thermo Fisher Scientific). Fixation was performed by using 4% paraformaldehyde (Wako Pure Chemical Industries, Osaka, Japan) or cold acetone (Wako Pure Chemical Industries). For blocking buffer, 5-10% skim milk (BD bioscience) or 3% FBS (Thermo Fisher Scientific) was used. Primary antibodies used for immunohistochemistry were rabbit anti-CK19 polyclonal antibody, rat anti-EpCAM monoclonal antibody, rabbit anti-EpCAM polyclonal antibody, rabbit polyclonal anti-Laminin α5 antibody (a kind gift from Dr. Jeffrey H. Miner), rabbit anti-PECAM polyclonal antibody, rat anti-Ki67 monoclonal antibody and rat anti-Lutheran monoclonal antibody. The information about antibodies is described in Table1. All images were captured using KEYENCE BZ-X710:BZ-X Viewer, Zeiss Axio observer z1: AxioCamHR3 or Olympus FV3000. The ratio of Ki67+ cell per EpCAM+ cell was calculated using Hybrid Cell Count function in the Dual Signal Extraction mode of BZ-X Analyzer. An average value of three random images per mouse was treated as a representative value for the mouse. Quantification of the distance of biliary cell cluster/cell from the center of the portal vein was performed using a previously reported method (Best et al., 2016). Briefly, the distance from the center of the portal
vein to the most distal EpCAM-stained cell was measured, and then the mean
diameter of the portal vein was subtracted from this value to eliminate the influence of
the size of the portal vein. An average value of six to fourteen random images of portal
region per mouse was treated as a representative value for the mouse.

Three-dimensional Culture

For three-dimensional culture, Cellmatrix Type I-A (Nitta Gelatin, Osaka, Japan) and
Matrigel with Growth Factor Reduced (Corning, MA, USA) were used for gel
components. Chilled cellmatrix and Matrigel were mixed at 1:9 ratio and used to coat
the surface of the culture dish. After solidification of the coating layer by incubating at
37°C, the mixture of cell suspension and gel at 1:1 ratio was added. After 30 minutes
of incubation at 37°C in 5% CO₂ chamber, culture medium was loaded on top of the
double-layered gel. The top layer of medium was changed twice a week. All images
were captured using DS-Fi2-L3 (Nikon Corporation, Tokyo, Japan) under a
phase-contrast microscope (Nikon ECLIPSE TS100, Nikon Corporation) after 6-12
days of culture. For the experiments using neutralizing and activating antibodies
against Itgb1, Hamster anti-rat CD29 (555002, BD Biosciences) and TS2/16 (303010,
Biolegend) were added in the culture at a final concentration of 5 μg/mL and 50 μg/mL,
respectively. For each control, Hamster IgM, λ1 isotype control (553957, BD
Pharmingen) or Mouse IgG1, κ isotype control (401404, Biolegend) were used. For
quantification of the size and formation efficiency of cyst, 50 cells were cultured in
individual wells of a 96-well plate. After 6 days of culture, the image was captured by a
phase-contrast microscope. All visible cell clusters were counted according to the
diameter of lumen. The cell cluster devoid of luminal structure was counted as “Cell
aggregate”.


Establishment of Lu-expressing Lu− BC by retroviral vector

For overexpression of mouse Lu (mLu) in Lu− BC, Bcam cDNA was amplified with two primers 3'- CTCGAGTCACTGCGCCGCTGAG -5' and 3'- GTCGACTTACATTCCCTGAGGAAG -5' by RT-PCR and inserted into the EcoRI and XhoI restriction enzyme sites of pMxs-IG plasmid vector (kindly provided by Dr. Kitamura) was used. For the production of retrovirus, pMxs-mLu-IG or pMxs-IG was transfected into the packaging cell line Platinum-E (Morita et al., 2000) by using lipofectamine 2000 (Invitrogen). The culture supernatant was centrifuged at 6,000g at 4°C overnight to recover virus particles. The precipitated virus particles were dissolved in culture medium and used to infect Lu− BC. After 16-24 hours, the culture media was replaced with fresh media and the culture was continued overnight. The cells expressing both mLu and GFP or only GFP were sorted by FACS and named as Lu− BC-mLu or Lu− BC-GFP, respectively.

RNA Extraction and Reverse Transcription

RNA extraction was performed using ISOSPIN Cell and Tissue RNA (NIPPON GENE, Toyama, Japan) according to the manufacturer’s instruction. For tissue homogenization, FastPrep-24 (MP Biomedicals) was used. Reverse transcription from RNA to cDNA was performed by PrimeScript RT Master Mix (Takara-bio, Shiga, Japan).

Quantitative Real-time PCR

Quantitative real-time PCR was performed using LightCycler480 (Roche, Basel, Switzerland) with the Universal Probe Library system. The sequence of used primers

**Generation of Bcam/Lu Deficient Mice**

pT7-sgRNA and pT7-hCas9 plasmid were kindly provided from Dr. Ikawa (Osaka University, Japan) (Mashiko et al., 2013). After digestion with EcoRI, Bcam mRNA synthesis was performed using an in vitro RNA transcription kit (mMESSAGE mMACHINE T7 Ultra Kit, Thermo Fisher Scientific), according to the manufacturer’s instructions. A pair of oligos targeting Bcam gene was annealed and inserted into the BbsI site of the pT7-sgRNA vector. The sequences of the oligos were as follows: Bcam/Lu (5’- AAC CCC CTG ACG CCC GCG CA -3’), which is located at exon 1 of Bcam/Lu gene. After digestion with XbaI, gRNAs were synthesized using the MEGAscript Kit (Thermo Fisher Scientific). The precipitated RNA was dissolved in Opti-MEM I (Thermo Fisher Scientific) at 0.4 μg/μL. C57BL/6N female mice (Clea-Japan Inc.) were used in this study. IVF was performed according to the Center for Animal Resources and Development’s (at Kumamoto University, Japan) protocol (http://card.medic.kumamoto-u.ac.jp/card/english/sigen/manual/onlinemanual.html). Electroporated embryos were cultured in KSOM medium, and transferred the next day to the oviducts of pseudo-pregnant females on the day of vaginal plug detection. Genome Editor electroporator and LF501PT1-10 platinum plate electrode (BEX
Co.Ltd., Tokyo, Japan) were used for electroporation. 50 embryos prepared were subjected to electroporation. The collected embryos cultured in KSOM medium were placed in the electrode gap filled with 5 μl of Opti-MEM I containing sgRNA and hCas9 mRNA. The electroporation conditions were 25V, 5 times. The eggs were then cultured in KSOM medium at 37°C and 5% CO₂ in an incubator until the two-cell stage.

**Human Tissue and Immunohistochemistry**

Three individual surgical specimens of cirrhotic liver were obtained from the patients with hepatocellular carcinoma. The deparaffinized and rehydrated sections were microwaved in EDTA buffer (pH 9.0) for 20 min in a microwave oven. Following endogenous peroxidase blocking, these sections were incubated at 4°C overnight with rabbit anti-CD239 monoclonal antibody against human Lutheran/BCAM (1:100 dilution, Epitomics, CA, USA) and then at RT for 1h with goat anti-rabbit immunoglobulins conjugated to peroxidase labeled-dextran polymer (K4003, Envision, Dako, Tokyo, Japan). After benzidine reaction, sections were lightly counterstained with hematoxylin.

**Statistical Analysis**

Statistical analyses and the determination of p value were performed using GraphPad Prism software. Statistical significance between two groups was evaluated using Mann-Whitney U test and considered for p<0.05. For comparison of four groups, one-way analysis of variance (ANOVA) was applied, and once F-test was significant, multiple comparisons between each group were conducted by Tukey’s multiple comparisons. Statistical significance was set at two-tailed p values < 0.05. Values
derived from at least four biological replicates were plotted in a graph with mean and
standard deviation. The exact number of biological samples was described in each
figure legend and source data. There was no exclusion of outliers in all experiments.
Group allocation was performed without any bias. A statistical method of sample size
calculation was not used during study design.

Acknowledgements

We would like to thank Dr. Jeffrey H Miner (Washington University, St Louis, MO) for
supplying anti-Laminin alpha5, and Dr. Toshio Kitamura (The University of Tokyo,
Tokyo, Japan) for providing a retroviral vector, pMxs/IRES-GFP. We also thank C.Y.
Kok for her editorial assistance, Y. Kamiya for mouse and technical assistance, C.
Koga for cell sorting, the University of Tokyo IMCB Olympus Bioimaging Center
(TOBIC) for acquiring image data, and the members of the Miyajima and Okochi
laboratory for their helpful discussion and suggestions.
References


Figure Legends

Figure 1. Phenotypic difference of DR and biliary cells between the CDE model and DDC model. (A) Immunohistochemical analysis of CDE-fed and DDC-fed mouse liver sections for EpCAM. (B) Co-localization of EpCAM and Lu in CDE-fed and DDC-fed mouse liver sections. (C) Comparison of Lu expression level in EpCAM+ cells among normal diet-fed, CDE-fed and DDC-fed mouse livers by flow cytometric analysis. PV: portal vein. Scale bar: 100 μm.

Figure 2. Culture of Lu+ and Lu− BC isolated from injured liver. (A) Representative images of Lu+ BC and Lu− BC by bright field microscopy. (B) Immunocytochemistry for F-actin in cultured Lu+ BC and Lu− BC. Arrowhead indicates pseudopod. (C) Flow cytometric analysis of Lu, Sca1, CD24, CD44, and CD71 expression levels in Lu+ BC and Lu− BC. The cultured Lu+ BC and Lu− BC were used for analysis after 6 passages. Scale bar: 100 μm.

Figure 3. Evaluation of Lu− BC and Lu+ BC characteristics by scratch assay and cyst formation assay. (A) Scratch assay using Lu− BC or Lu− BC. Representative images of day 0, day 1, and day 2 after scratch are shown. Quantitative data of cell moving distance at day 1 are plotted in a graph with mean and standard deviation. n = 4 biological replicates. Dotted line indicates cell front of scratched gap. (B) Schematic diagram of three-dimensional culture and cyst generation. (C) Bright field microscopic image of three-dimensionally cultured Lu+ BC and Lu− BC at culture day 4 or day 6. Arrows and arrowheads point to cysts and cell aggregates, respectively. The details of formed cysts are shown below. The cell cluster devoid of luminal structure was regarded as “Cell aggregate”. Scale bar: 100 μm.
Figure 4. Lu regulates the motility and cyst formation capacities of biliary cells.

(A) Schematic description for generating Lu− BC-mLu or Lu− BC-GFP by using retrovirus vector. Flow cytometric analyses show expression level of Lu and GFP. Bright field microscopic images show morphological change in Lu− BC-mLu. (B) Scratch assay using Lu− BC-GFP or Lu− BC-mLu. Representative images of day 0, day 1, and day 2 after scratch are shown. Quantitative data of cell moving distance at day 1 are plotted in a graph with mean and standard deviation. n = 5 biological replicates. Dotted line indicates cell front of scratched gap. (C) Bright field microscopic image of three-dimensionally cultured Lu− BC-GFP or Lu− BC-mLu at culture day 6. Arrows and arrowheads point to cysts and cell aggregates, respectively. The details of formed cysts are shown below. The cell cluster devoid of luminal structure was regarded as “Cell aggregate”. Scale bar: 100 μm.

Figure 5. Itgb1 signaling is critical for regulating the phenotype of biliary cells.

(A) Expression analysis for Lama5 in injured liver. Co-staining of EpCAM and Lama5 was performed in liver sections of CDE-fed mouse and DDC-fed mouse. (B) Evaluation of Lama5 gene expression in EpCAM+ cells isolated from CDE-fed and DDC-fed mouse livers by quantitative RT-PCR. Data are plotted in a graph with mean and standard deviation. n = 4 biological replicates. n.s.: not significance. (C) Scratch assay using Lu− BC in the presence or absence of Itgb1 neutralizing antibody. Hamster IgM was used as control. Representative images of day 0, day 1, and day 2 after scratch are shown. Dotted line indicates cell front of scratched gap. Quantitative data of cell moving distance at day 1 are plotted in a graph with mean and standard deviation. n = 4 biological replicates. (D) Bright field microscopic image of
three-dimensionally cultured Lu− BC-GFP at culture day 12 in the presence of Itgb1 neutralizing antibody or control IgM. Arrows and arrowheads point to cysts and cell aggregates, respectively. The details of formed cysts are shown below. The cell cluster devoid of luminal structure was regarded as “Cell aggregate”. Scale bar: 100 μm.

Figure 6. Bcam KO mice show drastic phenotype change in DR. (A) Schematic diagram of experiments using Bcam KO mouse. (B) Co-staining of EpCAM and Ki67 in WT and Bcam KO mouse liver sections in the CDE model. The ratio of Ki67+ cell per EpCAM+ cell is plotted in a graph with mean and standard deviation. n = 4 biological replicates. n.s.: not significance. (C) Co-staining of EpCAM and Lu in CDE-fed WT and Bcam KO mouse liver sections. (D) Quantitative analysis for the distance from portal vein to distal biliary cells in the CDE and DDC models. Data are plotted in a graph with mean and standard deviation. Statistical significance among groups is determined using one-way ANOVA. n = 5 biological replicates. (E) Immunostaining of EpCAM in WT and Bcam KO mouse liver sections in the DDC model. (F) Magnified immunohistochemical image of DR in CDE-fed and DDC-fed Bcam KO mouse liver. (G) Morphological image of EpCAM+ cells sorted from WT and Bcam KO mouse fed a CDE diet for 3 weeks. The cells were directly stained with Phalloidin to visualize F-actin 72 hours after plating on culture dish. Arrowhead points to pseudopod. Scale bar: 100 μm.

Figure 7. Expression of CD239 in human liver disease. Immunohistochemical images for Lu/BCAM (CD239) in human liver disease are shown. Cirrhotic liver sections obtained from the patients of non-alcoholic
steatohepatitis (A), hepatitis B virus (B) and hepatitis C virus (C) were stained. DRs are denoted with arrows.

Figure 8. Graphical abstract of this study.
Figure Supplement Legends

Figure 1-figure supplement 1. Immunohistochemical analysis of CDE-fed and DDC-fed mouse liver sections with anti-CK19 antibody. The LPCs in the CDE model exhibit spindle like shape forming primitive ductules, while those in the DDC model show obvious duct structure. Scale bar: 50 μm.

Figure 1-figure supplement 2. Expression analysis for PECAM and Lu in normal and injured liver. Co-staining of PECAM and Lu was performed in liver sections of normal diet- and DDC-fed mouse liver. Arrows show a doubly stained hepatic artery. PV: portal vein. Scale bar: 100 μm.

Figure 1-figure supplement 3. Co-staining of EpCAM and Lu in liver sections of normal liver. Arrows and arrowheads point to hepatic arteries and bile ducts, respectively. The fluorescence signal of Lu is weakly detected in EpCAM⁺ bile ducts, while it is saturated in EpCAM⁻ hepatic arteries in this setting of exposure. PV: portal vein. Scale bar: 100 μm.

Figure 1-figure supplement 4. Validation of specific reactivity of the used antibody to Lutheran. Ba/F3 cell, a murine pro B-cell line, was transduced with retroviral vector containing cDNA encoding mouse Lu and green fluorescent protein (GFP). By FCM analysis, the only GFP-positive cells that express Lu shift with anti-Lu antibody.

Figure 2-figure supplement 1. Expression profile of EpCAM, Lu and PECAM in non-parenchymal cells (NPCs) prepared from CDE-injured livers. NPCs were
analyzed by flow cytometry after triple staining with anti-EpCAM, anti-Lu and anti-PECAM antibodies. (A) FCM analysis of EpCAM, Lu and PECAM expression. EpCAM⁺ fraction is clearly distinguished from PECAM⁺ fraction by FACS. (B) Gating strategy for the isolation of EpCAM⁺ cells by FACS. There is no contamination of PECAM⁺ cells in the gate of EpCAM⁺Lu⁺ biliary cells.

Figure2-figure supplement 2. Immunocytochemistry for F-actin in cultured EpCAM⁺ cells isolated from normal liver. The image was acquired 7 days after primary culture. The attached cells showed a mixture of round and indefinite shape. Scale bar: 100 μm.

Figure5-figure supplement 1. Schematic model of the inhibitory effect of Lutheran on Integrin signaling. Lama5-containing laminins are able to bind to both Lutheran and Integrinα3β1/α6β1. High expression of Lutheran in LPC inhibits β1 Integrin signaling mediated by Laminin-511/521 competitively.

Figure5-figure supplement 2. Gene expression analysis of Itga3, Itga6 and Itgb1 mRNA in Lu⁻ and Lu⁺ BC by quantitative RT-PCR. Relative expression level is plotted in a graph with mean and standard deviation (n = 4). n.s.: not significance.

Figure5-figure supplement 3. Gene expression analysis of Bcam mRNA in Lu⁻ BC. Lu⁻ BC cultured in the presence or absence of neutralizing anti-Itgb1 antibody was analyzed by quantitative RT-PCR. Lu⁺ BC was used as a positive control. Relative expression level is plotted in a graph with mean and standard deviation (n = 4). n.d.: not detected.
Figure 5-figure supplement 4. Cyst formation assay of Lu+ cells in the presence of activating anti-Itgb1 antibody (TS2/16) or control IgM. Representative images of cultured Lu+ BC at culture day 6 are shown. Arrow and arrowhead point to a cyst and a cell aggregate, respectively. The details of formed cysts are shown below. The cell cluster devoid of luminal structure was regarded as “Cell aggregate”. Scale bar: 100 μm.

Figure 6-figure supplement 1. Generation of Bcam KO mouse by using the CRISPR/Cas9 method. Schematic illustration of the mouse Lu/Bcam gene structure and sequences around the targeted allele. Blue and red letters stand for an initiation ATG codon and the deleted sequence (11bp) in KO mouse, respectively. The sequence for gRNA and protospacer-adjacent motif (PAM) are underlined. Genomic PCR of WT and Bcam KO mice using a set of Primer 1 and Primer 2 yields amplicon corresponding to 201bp and 190bp, respectively.
Information on Source data

Figure 3-source data 1

Figure 3A: Numerical data for measurements of migrating distance in the scratch assay using Lu⁻ BC and Lu⁺ BC.

Figure 3C: Numerical data for the details of formed cyst in the 3D culture using Lu⁻ BC and Lu⁺ BC.

Figure 4-source data 1

Figure 4B: Numerical data for measurements of migrating distance in the scratch assay using Lu⁻ BC-GFP and Lu⁻ BC-mLu.

Figure 4C: Numerical data for the details of formed cyst in the 3D culture using Lu⁻ BC-GFP and Lu⁻ BC-mLu.

Figure 5-source data 1

Figure 5B: Numerical data for expression analysis of Lama5 mRNA in EpCAM⁺ cells by real-time RT PCR

Figure 5C: Numerical data for measurements of migrating distance in the scratch assay using Lu⁻ BC in the presence or absence of neutralizing anti-Itgb1 antibody.

Figure 5D: Numerical data for the details of formed cyst in the 3D culture using Lu⁻ BC in the presence or absence of neutralizing anti-Itgb1 antibody.

Figure 6-source data 1

Figure 6B: Numerical data for the ratio of Ki67⁺ cells per EpCAM⁺ cells

Figure 6D: Numerical data for measurements of the distance from portal vein to
distal biliary cells in the CDE and DDC models.

Figure 5-Supplement 2-source data 1
Numerical data for expression analysis of Itga3, Itga6 and Itgb1 mRNA in Lu⁺ BC and Lu⁻ BC by real-time RT PCR

Figure 5-Supplement 3-source data 1
Numerical data for expression analysis of Bcam mRNA in Lu⁻ BC by real-time RT PCR

Figure 5-Supplement 4-source data 1
Numerical data for the details of formed cyst in the 3D culture using Lu⁺ BC in the presence or absence of activating anti-Itgb1 antibody (TS2/16).
Figure 1

A

CDE

EpCAM

Hoechst

DDC

B

EpCAM

Lu

EpCAM Lu Hoechst

C

Normal diet

CDE

DDC

EpCAM

Lu

Potential PV
Figure 2

A

Lu⁺ BC

Lu⁻ BC

B

Lu⁺ BC

Lu⁻ BC

C

Lu⁺ BC

Lu⁻ BC

Lu

Sca1

CD24

CD44

CD71

Isotype Control

Stained Sample

Hoechst F-actin

Bar scale
Figure 3

(A) Lu\(^-\) BC and Lu\(^+\) BC at Day 0, Day 1, and Day 2.

(B) 3D-culture of LPC in a mixture of Matrigel and Collagen I.

(C) Lu\(^-\) BC and Lu\(^+\) BC at Day 4 and Day 6.

(D) Bar graph showing the moving distance relative to time for Lu\(^-\) BC and Lu\(^+\) BC.

(E) Graph showing the percentage distribution of different size categories for Lu\(^-\) BC and Lu\(^+\) BC.
Figure 4

A

Gene transfer via retrovirus

Lu- BC

EpCAM

EpCAM

Isotype Control

Stained Sample

GFP

GFP

GFP (control)

Lu- IRES-GFP

Lu- BC-GFP

Lu- BC-mLu

B

Day 0

Day 1

Day 2

Lu- BC-GFP

Lu- BC-mLu

C

Lu- BC-GFP

Lu- BC-mLu

Moving Distance (relative)

p = 0.0079

Lu- BC-GFP

Lu- BC-mLu

> 10 μm

Lumen

1 - 10 μm

Lumen

Cell aggregate

[ % ]
Figure 5

A  
EpCAM  
Lama5  
EpCAM Lama5 Hoechst  
CDE  
DDC  

B  
Relative expression (I/ActB)  
CDE EpCAM⁺  
DDC EpCAM⁺  
n.s.  

C  
Lu⁻ BC  
Control  
α-Ltgb1 (neutralizing)  
Day 0  
Day 1  
Day 2  

D  
Lu⁻ BC  
Control  
α-Ltgb1 (neutralizing)  

p = 0.057  

[Graph showing relative expression (I/ActB) for CDE and DDC, with EpCAM⁺ highlighted.]

[Comparison of control and α-Ltgb1 (neutralizing) conditions over three days (Day 0, Day 1, Day 2).]

[Bar chart showing percentage distribution of lumen sizes (< 10 μm, 1 - 10 μm, > 10 μm, cell aggregate) for Control and α-Ltgb1 (neutralizing).]
Figure 6

A. Schematic diagram showing the genetic modification in wildtype and knockout mice.

B. Immunohistochemistry (IHC) of injured liver with anti-EpCAM Ab.

C. Graph showing Ki67+/EpCAM⁺ percentage.

D. Graph showing distance from portal vein (relative).

E. Comparison of WT and Bcam KO under DDC diet.

F. Comparison of CDE and DDC diets in Bcam KO.

G. Comparison of WT and Bcam KO under CDE diet.
Figure 8

Healthy vs. Pathological

Healthy:
- Portal Vein
- Hepatic Artery
- Bile Duct
- Bile Canaliculus
- Cholangiocyte
- Canal of Hering
- Hepatocyte

Healthy Pathways:
- CDE Injury
- DDC Injury

Pathological:
- Invasive BC
- Duct-forming BC

Pathological Area:
- Injury Area
- Lu^+ (High)
- Lu^-/low
Figure 1-figure supplement 1

CDE

DDC

Scale bar: 50 μm
Figure 1-figure supplement 2

Normal diet

PECAM

Lu

Lu PECAM Hoechst

DDC

PV

PV
Figure 1-figure supplement 4

Ba/F3-mLu IRES GFP

iso

GFP

Lu

GFP
Figure 2-figure supplement 1

A

EpCAM vs. PECAM

B

EpCAM+ cell vs. Lu

Lu+ BC

% of Max

Isotype control

PECAM
Figure 5-figure supplement 1

DDC Injury
Downregulation of Lutheran

Laminin 511
Integrin β1
ECM adhesion ↑
Signal
Duct formation ↑
Motility ↓

CDE Injury
Upregulation of Lutheran

Laminin 511
Integrin β1
Lutheran
Competitive Inhibition
Duct formation ↓
Motility ↑
Figure 5-figure supplement 2

Itga3

Itga6

Itgb1

Relative expression (ActB)

n.s.

n.s.

n.s.

Lu− BC  Lu+ BC

Lu− BC  Lu+ BC

Lu− BC  Lu+ BC
Figure 5-figure supplement 3

$B_{cam}$

Relative expression (/ActB)

n.d.  n.d.

Lu$^{-}$ BC (control)  Lu$^{-}$ BC (neutralizing AB)  Lu$^{+}$ BC

(a-Itgb1)
Figure 6-figure supplement 1

Primer 1 *Bcam_F1g:* 5’ GACAGCAGGAAGGTGAGCC 3’
Primer 2 *Bcam_R1g:* 5’ AGGGCAGTGGGAGGTCTTG 3’

Wild type mouse amplicon
AGGGCAGTGGGAGGTCTTGAGGCCTTGCCCTGCGCCCAAGCTTGGGGAGTTGGGCGTGGTCAGGGG
CGTTGTCAGGGGCGCTGCCTCCGCTCCAGCTTCAGGCGGCGGCGGAGAGCTGCTCCTCGCCCGGGTCT
CAGTCACTGCGCCACTGCAGGGAACATG**AACCCTGACGCCCCCAGAGGGGGCT**GCTGCTGCTG
GGTCACCTTCCTTGCTGTC (201 bp)

Guide RNA

PAM sequence

Initiation Deleted sequence in knockout mouse

Knockout mouse amplicon (11bp deletion)
AGGGCAGTGGGAGGTCTTGAGGCCTTGCCCTGCGCCCAAGCTTGGGGAGTTGGGCGTGGTCAGGGG
CGTTGTCAGGGGCGCTGCCTCCGCTCCAGCTTCAGGCGGCGGCGGAGAGCTGCTCCTCGCCCGGGTCT
CAGTCACTGCGCCACTGCAGGGAACATGAACCCCTGACGCTGCTGCTGCTGGCTCAGCTTTCTG
CTGTC (190 bp)